journal cover

The influence of Aclacinomycin A on the immune response and on experimental immune disorders

International Journal of Immunopharmacology

Jan 1, 1984

G DickneiteH H Sedlacek

PMID: 6332788

Abstract

The anti-cancer drug Aclacinomycin A (ACM) was able to inhibit the humoral immune response of mice against sheep red blood cells. This could be demonstrated in the formation of antibody secreting cells (PFC) and serum antibody titers, when ACM was administered either together with the a...read more

Mentioned in this Paper

Immune Response
Antineoplastic Agents
T-Lymphocyte
Immune System Diseases
Murine
Red blood cells, blood product
Bright Disease
Antibody Titer Measurement
Aclarubicin
Experimental Autoimmune Encephalomyelitis
Paper Details
References
  • References13
  • Citations2
12

Similar Papers Found In These Feeds

Therapy for Autoimmunity

Currently treatments for autoimmune diseases are anti-inflammatory and immunosuppressive, although recent advances in regulatory T cell therapy have shown promise as a potential therapeutic strategy. Discover the latest research on Therapies for Autoimmunity here.

Experimental Autoimmune Encephalomyelitis

Experimental autoimmune encephalomyelitis is a commonly used experimental model for autoimmune central nervous system diseases, most notably multiple sclerosis. Here is the latest research on experimental autoimmune encephalomyelitis.

Encephalomyelitis

Encephalomyelitis is characterized by inflammation of the brain or spinal cord. This includes acute disseminated encephalomyelitis, which can be caused by viral infection and characterized by damage to the myelin sheath. Discover the latest research on encephalomyelitis here.

Immune Complexes

Immune complexes are formed by the binding of antibodies to soluble antigens eliciting an immune response and are prevalent in autoimmune diseases. Discover the latest research on Immune Complexes here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Hemolytic-uremic syndrome

Hemolytic-uremic anemia (HUS) is characterized by non-immune hemolytic anemia and thrombocytopenia as well as organ dysfunction, typically acute renal failure. HUS is often caused by Shiga toxin-producing enterohaemorrhagic Escherichia coli, while atypical HUS is associated with complement dysregulation. Find the latest research on HUS here.

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

Immunogenetics of Multiple Sclerosis

Multiple sclerosis (MS) was one of the first conditions shown to be associated with HLA class II factors. Find the latest research on MS here, including HLA studies providing insights on the genetics of the susceptibility to MS.

Immunosuppression

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

© 2020 Meta ULC. All rights reserved

The influence of Aclacinomycin A on the immune response and on experimental immune disorders

International Journal of Immunopharmacology

Jan 1, 1984

G DickneiteH H Sedlacek

PMID: 6332788

DOI:

Abstract

The anti-cancer drug Aclacinomycin A (ACM) was able to inhibit the humoral immune response of mice against sheep red blood cells. This could be demonstrated in the formation of antibody secreting cells (PFC) and serum antibody titers, when ACM was administered either together with the a...read more

Mentioned in this Paper

Immune Response
Antineoplastic Agents
T-Lymphocyte
Immune System Diseases
Murine
Red blood cells, blood product
Bright Disease
Antibody Titer Measurement
Aclarubicin
Experimental Autoimmune Encephalomyelitis

Similar Papers Found In These Feeds

Therapy for Autoimmunity

Currently treatments for autoimmune diseases are anti-inflammatory and immunosuppressive, although recent advances in regulatory T cell therapy have shown promise as a potential therapeutic strategy. Discover the latest research on Therapies for Autoimmunity here.

Experimental Autoimmune Encephalomyelitis

Experimental autoimmune encephalomyelitis is a commonly used experimental model for autoimmune central nervous system diseases, most notably multiple sclerosis. Here is the latest research on experimental autoimmune encephalomyelitis.

Related Papers

European Journal of Cancer & Clinical Oncology

Mutagenicity of eight anthracycline derivatives in five strains of Salmonella typhimurium

European Journal of Cancer & Clinical OncologyMay 1, 1983
D MarzinG Mathe
Paper Details
References
  • References13
  • Citations2
12
/papers/the-influence-of-aclacinomycin-a-on-the-immune/6332788